Evaluation of an AI-Driven Risk Stratification System for Clinical Deterioration in Patients With Geriatric Hip Fracture

OBJECTIVES: To determine whether an artificial intelligence–driven Clinical Deterioration Index (CDI) could identify geriatric patients with hip fracture at risk of early postoperative complications and to establish an orthopaedic-specific cutoff that identified patients at risk of deterioration. METHODS: Design: Retrospective cohort study. Setting: Single Level I trauma center. Patient Selection Criteria: Patients younger than 65 years of age who underwent fixation of OTA/AO 31-A/B/C hip fractures between June 2022 and December 2023 were included using ICD-10 codes S72.0-, S72.1-, and S72.2-. Exclusion criteria were pathologic fracture, revision surgery, or absence of 30-day follow-up. The CDI uses 31 clinical measures to generate a score from 0 to 100 reflecting risk of rapid deterioration. Patients were separated into 2 groups based on peak CDI in the immediate 48-hour postoperative period: CDI ≥65 and CDI Outcome Measures and Comparisons: Primary outcomes were in-hospital complications (cognitive changes, cardiac complications, DVT/PE, etc). Secondary outcomes included length of stay, ambulation distance, and 1-year mortality. Outcomes were compared between CDI groups. RESULTS: Of 197 patients (age range 65–98, 66% female), 15 (7.6%) exceeded the baseline CDI threshold of 65. This group had higher complication rates (93.3% vs. 26.4%, P P = 0.047), reduced ambulation at discharge (8.8 vs. 42.3 feet, P P = 0.02). CDI ≥65 was associated with postoperative complications (OR 37.9). The institutional cutoff of 65 offered high specificity (99.3%) but low sensitivity (22.6%). An optimized threshold (47.7) improved sensitivity (77.4%) with comparable accuracy (75.0%). CONCLUSIONS: An elevated Clinical Deterioration Index (CDI) ≥ 65 correlated with poor outcomes in geriatric patients with hip fracture. Specialty-specific cutoffs showed potential to improve postoperative risk stratification and identification of higher-risk patients. LEVEL OF EVIDENCE: Therapeutic Level III (retrospective cohort study). See Instructions for Authors for a complete description of levels of evidence.